-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lenvatinib (lenvatinib) is a multi-target (VEGFR-1, VEGFR-2, VEGFR-3, FGFR1, PDGFR, cKit, Ret) receptor kinase inhibitor , which can prevent cancer cells in two ways Activities: 1.
Le cutting erlotinib (lenvatinib) is a multi-target (VEGFR-1, VEGFR-2 , VEGFR-3, FGFR1, PDGFR, cKit, Ret) receptor kinase inhibitor, vascular
In South Korea, lenvatinib is approved as a first-line treatment option for patients with unresectable hepatocellular carcinoma (HCC).
This study aims to evaluate the effectiveness and safety of levatinib in real practice, and to find prognostic factors related to survival and disease progression.
Researchers conducted a hospital-based retrospective study on 116 patients with unresectable HCC who received lenvatinib treatment at Samsung Medical Center from October 2018 to March 2020; 5 patients had adverse reactions (AE) Interruption of lenvatinib treatment was excluded from the efficacy analysis (n=111), and the safety analysis included 116 patients.
Tumor volume change
Tumor volume changeOverall survival and progression-free survival
Overall survival and progression-free survivalThe median age of 111 patients was 59 years old, and the median follow-up time was 6.
Kaplan-Meier estimated that the overall survival was 10.
Adverse reactions
Adverse reactions86/116 (74.
86/116 (74.
Multivariate analysis of overall survival
Multivariate analysis of overall survivalTumor occupying ≥50% of the liver, bone marrow insufficiency, and anorexia are all predictors of survival and prognosis, and diarrhea is a favorable factor for disease progression.
In summary, lenvatinib treatment has shown good efficacy and safety in practical applications .
The treatment of lenvatinib has shown good efficacy and safety in practical applications.
Original source:
Goh Myung Ji,Oh Joo Hyun,Park Yewan et al.
org/10.
1159/000512239">Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea in this message
